Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Non-Insulin Therapies for Diabetes Market to Reach USD 58.6 Billion by 2034, Driven by Innovative Drug Mechanisms and Rising Global Awareness | States TMR

This image opens in the lightbox

News provided by

Transparency Market Research

01 Aug, 2024, 14:16 GMT

Share this article

Share toX

Share this article

Share toX

The global non-insulin therapies for diabetes market is slated to grow on an exponential note with a sizable increase in incidence of type 2 diabetes followed by governments and non-government agencies collaborating to devise better measures to cure it, with non-insulin therapies being the epicentre.

WILMINGTON, Del., Aug. 1, 2024 /PRNewswire/ -- The global non-insulin therapies for diabetes market is forecast to advance at a CAGR of 5.8% from 2024 to 2034. As per TMR's estimates, the market is slated to attain a US$ 58.6 billion valuations by the end of the aforementioned forecast period. As of 2023, the landscape was valued at US$ 31.8 billion.

Non-insulin therapies are generally preferred by healthcare personnel in patients suffering from type 2 diabetes, in which body either fails to produce enough insulin or is incapable of using the insulin that it produces. Certain non-insulin agents facilitate increase of insulin release from the pancreatic cells (sulfonylureas), whereas some of them increase glucose uptake peripherally and reduce hepatic glucose output (Biguanides).

There are agents slowing down digestion of starch in the small intestine (alpha glucosidase inhibitors). Certain medications facilitate reduction of post-meal sugar by blocking some enzymes (Incretin mimetics). The last decade has seen a drastic rise in launching and approvals of non-insulin therapies for diabetes. Various drugs under the category of SGL2 inhibitors such as Empagliflozin, Canagliflozin, and Dapagliflozin were launched after 2013.

Request for sample PDF copy of report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86328

Type 2 diabetes occurs in adults when body turns out to be resistant to insulin or does not produce insulin sufficient for the body. In other words, type 2 diabetes happens due to improper regulation of body sugar as fuel. As per the World Health Organization, 422 million people worldwide are living with diabetes, with 1.5 million succumbing to it. Need to combat type 2 diabetes through non-insulin therapies is thus driving the non-insulin therapies for diabetes market.

Key Takeaways from the Market Study

  • A valuation of US$ 33.6 billion is anticipated for the non-insulin therapies for diabetes market in 2024.
  • From 2024 to 2034, the market for non-insulin therapies for diabetes is slated to expand 1.7x.
  • By drug class, demand for SGLT2 inhibitors is anticipated to flourish throughout the forecast period, attributed to their minimal side effects.
  • Intramuscular administration of non-insulin therapies for diabetes to acquire greater popularity, amid the need for enhanced effectiveness.

Key Drivers and Trends

  • Non-insulin-based drugs for diabetes work toward the direction of lessening blood glucose level and keeping up for ideal glycemic control. For instance, certain operators increment insulin discharge from the pancreatic cells (Sulfonylureas), certain specialists increment the glucose take-up and decrease yield of hepatic glucose (Biguanides).
  • Some operators curtail assimilation of starch in the small digestive tract (alpha glucosidase inhibitors), and some prescriptions diminish post-supper sugar by obstruction of some chemicals.
  • The World Health Organization states that diabetes is amongst the top 3 causes of fatalities amongst the non-communicable diseases across the globe. Governments are collaborating with various research institutes, hospitals, and non-government agencies to create awareness regarding type 2 diabetes and curative measures regarding the same.

Non-Insulin Therapies for Diabetes Market Report Scope:

Report Coverage

Details 

Forecast Period  

2024-2034

Base Year  

2020-2022

Size in 2023

US$ 31.8 Bn

Forecast (Value) in 2034

US$ 58.6 Bn

Growth Rate (CAGR) 

5.8 %

No. of Pages 

142 Pages 

Segments covered 

By Drug Class, By Route of Administration, By Distribution Channel, By Region

Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86328

Regional Profile

  • North America dominated the non-insulin injection landscape in 2023 and the scenario is expected to persist during the forecast period. This is attributed to rise in incidence of type 2 diabetes in the U.S. followed by sizable spending on healthcare.
  • As per the Centers for Disease Control and Prevention, over 38 million Americans suffer from diabetes, with around 90-95% contracting type 2 diabetes.
  • Asia Pacific is another promising investment hub for non-insulin therapy providers. Asia Pacific's non-insulin therapies for diabetes market growth is ascribed to growing awareness about the importance of non-insulin treatments for type 2 diabetes.
  • As per the National Institutes of Health, 23-30% of the youth over here suffers from type 2 diabetes and the percentage is expected to rise during the forecast period.

Competitive Landscape

From organizing clinical trials to seeking regulatory approval, the non-insulin therapies for diabetes landscape is experiencing noteworthy developments. Companies are pooling in a substantial amount of resources to fund trials and research and development projects. Some key providers of non-insulin therapies for diabetes include:

  • GSK plc
  • Eli Lilly and Company
  • Sumitomo Pharma
  • Intarcia Therapeutics
  • Servier Laboratories
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Dong-A Pharmaceutical Co. Ltd.
  • Luye Pharma Group
  • Eurofarma Laboratories SA

Key Market Developments

  • In April 2024, GSK Plc announced that the U.S. Food and Drug Administration has approved its TazneumTM (albiglutide) product for injection and subcutaneous use for a once-a-week treatment for type 2 diabetes. Albigludite is a glucagon-like peptide-1 receptor agonist (GLP-1) for treating the condition.
  • In June 2023, Pfizer Inc. provided update on GLP-1-RA clinical development program for the adults suffering from obesity and type 2 diabetes mellitus, stating that it is continuing with advancement of the first full agonist oral candidate danudlipron toward late-state development.

Key Segments Covered

Drug Class

  • Biguanides
  • Sulfonylureas
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • DPP-4 Inhibitors
  • GLP-1 Analogs
  • Sodium-glucose co-transporter-2 (SGLT2) Inhibitors

Route of Administration

  • Oral
  • Intramuscular

End User

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Buy this Premium Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=86328&ltype=S

More Trending Reports by Transparency Market Research –

  • Consumer Genomics Market - The global consumer genomics market was estimated to have acquired US$ 2.4 billion in 2021. It is anticipated to register a 22.3% CAGR from 2022 to 2032 and by 2032, the market is likely to gain US$ 21.2 billion.
  • Acute Migraine Treatment Market - The global market for acute migraine treatment was estimated to be worth a market valuation of around US$ 2.1 billion in 2021. The market is anticipated to advance with a booming 15.1% CAGR from 2023 to 2031 and by 2031, the market is likely to gain US$ 7.9 billion.
  • Ceftriaxone Market - The global ceftriaxone market is projected to flourish at a CAGR of 2.9% from 2022 to 2031. A valuation of US$ 2.2 billion is anticipated for the market in 2031. As of 2023, the market for ceftriaxone is expected to close at US$ 1.79 billion.
  • Fusion Inhibitors Market - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to gain US$ 7.2 billion by 2031 securing a CAGR of 14.2% between 2022 and 2031.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg 

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.